4.9 • 876 Ratings
🗓️ 13 June 2025
⏱️ 27 minutes
🧾️ Download transcript
Listener feedback on cardiac sarcoidosis, SA node ablation, surgical AF ablation, chronic kidney disease protection, and recruiting for clinical trials are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
II IST
III Survival After Surgical AF ablation during CABG
IV Finerenone with Empagliflozin in CKD and DM
V Recruiting for Important Trials and the Stature of EP as a Profession
Two UK Cardiology Trials Struggle to Recruit Patients
https://www.medscape.com/viewarticle/two-uk-cardiology-trials-struggle-recruit-patients-2025a1000ffs
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
Click on a timestamp to play from that location
0:00.0 | You're listening to This Week in Cardiology from the heart.org, Medscape Cardiology. |
0:05.7 | This podcast is intended for health care professionals only. |
0:08.8 | Any views expressed are the presenters' own and do not necessarily reflect the views of WebMD or Medscape. |
0:14.8 | Hi, everyone. |
0:16.2 | This is John Mandrola from the Heart.org Medscape Cardiology, and this is this week in cardiology for June 13th, 2025. |
0:25.5 | Today I'm recording on a warm, sunny day in London, where I'm here to speak at the London Arithmetic Summit. |
0:32.9 | I'll talk today about listener feedback and cardiac sarcoidosis, sinus node ablation, surgical |
0:39.9 | a.F. Ablation, reducing outcomes in patients with chronic kidney disease, type 2 diabetes, |
0:46.3 | and recruiting for cardiac trials. The first topic is listener feedback on cardiac sarcoidosis. |
0:54.8 | Now, one of the best parts of this podcast is the listener feedback I receive. |
0:59.4 | This week, David Bernie, the Division Chief of Cardiology at the University of Ottawa, |
1:03.9 | and an academic electrophysiologist who's active in sarcoid research, |
1:08.6 | sent me feedback on a paper from Dutch and American authors that I had |
1:11.8 | covered two weeks ago on May 30, 2025. The mostly Dutch-led paper had 1,500 patients with biopsy-proven |
1:19.6 | established sarcoidosis, most of which were non-cardiac. The question they had was how to restratify |
1:26.4 | for an ICD. Now, the two ways of risk stratification |
1:30.1 | were to either use professional society recommendations or to use CMR. CMR was grouped into four categories, |
1:38.1 | one high-risk category, and the three were lower-risk categories. The high-risk category was, quote, |
1:44.0 | pathology-frequent LGEE. |
1:46.9 | The three main findings were that if either the professional society criteria or CMR |
1:53.1 | indicated a high risk, the rate of VT at five years, was also high. |
1:58.1 | Up to one in three patients had VT. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Medscape Podcasts, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Medscape Podcasts and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.